Wegovy Pill vs Foundayo: Which Oral GLP-1 Might Fit You?
By 2026 there are two oral GLP-1 options for weight loss on the US market: the Wegovy pill (oral semaglutide, from Novo Nordisk) and Foundayo (orforglipron, from Eli Lilly). Both are once-daily tablets that can help people lose weight, but they work differently and fit different routines. Understanding the practical differences helps you have a better conversation with your doctor.
The biggest day-to-day difference is how you take them. The Wegovy pill is a peptide, so it must be taken on an empty stomach with a sip of plain water, and you wait about 30 minutes before eating, drinking, or taking other pills. Foundayo is a small molecule, which means it can be taken at any time of day, with or without food and water, and no waiting. For a busy or irregular schedule, that flexibility can matter a lot.
On results and side effects, both belong to the same drug family. High-dose oral semaglutide can deliver strong weight loss, while orforglipron produced an average of about 12% at its highest dose in trials. Side effects are broadly similar - mostly nausea and other stomach issues that often ease over time - but individual responses vary. Supply and price also differ: small-molecule pills are easier to manufacture at large scale and need no cold chain.
So which is better? There is no universal answer. If the empty-stomach-and-wait rule is hard for you to keep, Foundayo's flexibility may suit you; if you are aiming for the highest possible weight loss, that is worth weighing with your doctor. Insurance coverage and monthly cost often decide it in practice. Talk to your doctor or pharmacist about which fits your health, your routine, and your budget. This is general information, not medical advice.